ESMO Media Releases

The European Society for Medical Oncology has selected Prof. Thomas Gajewski to receive the 2019 ESMO Award for Immuno-Oncology. 

New data have shown for the first time that targeted therapy can improve the outcome of patients diagnosed with advanced cholangiocarcinoma.

Targeting faulty DNA repair mechanisms in advanced castration resistant prostate cancer can slow progression and potentially improve survival, paving the way for a new approach to treatment of the most common form of cancer in men.

Patients with metastatic urothelial cancer have longer progression free survival when treated with first-line immunotherapy and chemotherapy instead of chemotherapy alone, according to late breaking results of the IMvigor130 trial presented at the ESMO Congress 2019 in Barcelona, Spain.

Patients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may provide important clues to novel treatment for the thousands of new cases each year.

A growing number of patients with advanced lung cancer could soon be offered a blood test to help to decide the best treatment for them instead of having to get a tumour sample for analysis.

New data from two studies reported at the ESMO Congress 2019 have shown that treatment with a CDK4/6 inhibitor plus fulvestrant improves overall survival in women with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer

Immune therapy added to chemotherapy improves pathological complete response in patients with early triple negative breast cancer, according to late breaking results from the KEYNOTE-522 trial presented at the ESMO Congress 2019 in Barcelona, Spain. 

New data show the benefit of a more intensive maintenance regimen for ovarian cancer with the PARP inhibitor olaparib added to bevacizumab, in an all-comers population, with and without a BRCA mutation. 

New data have shown that first-line treatment with a combination of two immunotherapy drugs improves overall survival in a subset of patients with advanced non-small cell lung cancer (NSCLC) compared to chemotherapy

First-line osimertinib significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC), according to late breaking results of the FLAURA trial presented at the ESMO Congress 2019 in Barcelona, Spain.

Liquid biopsy is likely to play an increasing role in identifying patients with colorectal cancer (CRC) who are likely to relapse after surgery, and has potential for optimising treatment for individual patients, according to new research presented at the ESMO Congress 2019.